

Prof. Esteban Cvitkovic completed his medical degree in Argentina in 1969, aged 19. With over 50 years of international specialized oncology practice and academic experience in Argentina, Italy, the US and France, Prof. Cvitkovic has authored over 230 peer-reviewed articles, and trained dozens of oncology specialists.

Focused on early-stage drug development and therapeutic optimisation, Prof. Cvitkovic has been instrumental in defining the clinical utility and enabling the registration of several oncology drugs including cisplatin, vindesine, bleomycin, navelbine, and amifostine. Oxaliplatin, irinotecan, docetaxel and ET-743 are amongst his milestone contributions, and he has a keen interest in rarer tumors including pancreatic cancer and soft tissue sarcomas.

Prof. Cvitkovic has established two oncology-specialized clinical CROs, Cvitkovic & Associés Consultants and Oncology Therapeutic Development, the latter of which he is currently CEO. He also co-founded OncoEthix, a biotech devoted to novel therapeutic leads and focused on the early development of the first bromodomain inhibitor, which was sold to Merck in 2014. He serves on scientific boards for several biotech companies and heads the Scientific Board of the FNAB.